Our top pick for
Building a portfolio
Aerie Pharmaceuticals, Inc is a drug manufacturers-specialty & generic business based in the US. Aerie Pharmaceuticals shares (AERI) are listed on the NASDAQ and all prices are listed in US Dollars. Aerie Pharmaceuticals employs 365 staff and has a trailing 12-month revenue of around USD$83.1 million.
|52-week range||USD$9.01 - USD$21.3|
|50-day moving average||USD$18.4321|
|200-day moving average||USD$14.5304|
|Wall St. target price||USD$27.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-5.169|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$83.1 million|
|Gross profit TTM||USD$55.5 million|
|Return on assets TTM||-22.77%|
|Return on equity TTM||-191.81%|
|Market capitalisation||USD$846.4 million|
TTM: trailing 12 months
There are currently 7.1 million Aerie Pharmaceuticals shares held short by investors – that's known as Aerie Pharmaceuticals's "short interest". This figure is 3.6% down from 7.3 million last month.
There are a few different ways that this level of interest in shorting Aerie Pharmaceuticals shares can be evaluated.
Aerie Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Aerie Pharmaceuticals shares currently shorted divided by the average quantity of Aerie Pharmaceuticals shares traded daily (recently around 714065.99190283). Aerie Pharmaceuticals's SIR currently stands at 9.88. In other words for every 100,000 Aerie Pharmaceuticals shares traded daily on the market, roughly 9880 shares are currently held short.
However Aerie Pharmaceuticals's short interest can also be evaluated against the total number of Aerie Pharmaceuticals shares, or, against the total number of tradable Aerie Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aerie Pharmaceuticals's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Aerie Pharmaceuticals shares in existence, roughly 150 shares are currently held short) or 0.2067% of the tradable shares (for every 100,000 tradable Aerie Pharmaceuticals shares, roughly 207 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Aerie Pharmaceuticals.
Find out more about how you can short Aerie Pharmaceuticals stock.
We're not expecting Aerie Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Aerie Pharmaceuticals's shares have ranged in value from as little as $9.01 up to $21.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aerie Pharmaceuticals's is 0.7248. This would suggest that Aerie Pharmaceuticals's shares are less volatile than average (for this exchange).
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.